Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes
暂无分享,去创建一个
T. Funahashi | I. Shimomura | A. Imagawa | N. Maeda | Y. Fujishima | J. Kozawa | Susumu Kashine | Aki Hiuge-Shimizu | K. Okita | Kana Inoue
[1] P. Reaven,et al. Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins , 2011, Cardiovascular diabetology.
[2] H. Grill,et al. Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4. , 2011, Endocrinology.
[3] A. Dear,et al. A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model , 2011, Diabetes & vascular disease research.
[4] R. Kawamori,et al. Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4 , 2010, Diabetes.
[5] Y. Nakaya,et al. Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression. , 2009, Biochemical and biophysical research communications.
[6] D. Matthews,et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue , 2009, Diabetes, obesity & metabolism.
[7] D. Andersen,et al. Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides. , 2009, The Journal of clinical endocrinology and metabolism.
[8] Weiping Jia,et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. , 2009, JAMA.
[9] F. Hu,et al. Dietary Fat Intake and Cognitive Decline in Women With Type 2 Diabetes , 2009, Diabetes Care.
[10] D. Matthews,et al. Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes , 2008, Diabetes Care.
[11] Y. Seino,et al. Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. , 2008, Diabetes research and clinical practice.
[12] Jennifer G. Robinson,et al. Low-fat dietary pattern and risk of treated diabetes mellitus in postmenopausal women: the Women's Health Initiative randomized controlled dietary modification trial. , 2008, Archives of internal medicine.
[13] L. B. Knudsen,et al. Liraglutide, a Once‐daily Human Glucagon‐like Peptide‐1 Analog, Minimizes Food Intake in Severely Obese Minipigs , 2007, Obesity.
[14] Parvez Hossain,et al. Obesity and diabetes in the developing world--a growing challenge. , 2007, The New England journal of medicine.
[15] Tanya Hansotia,et al. Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. , 2007, The Journal of clinical investigation.
[16] L. B. Knudsen,et al. Liraglutide, a Long-Acting Glucagon-Like Peptide-1 Analog, Reduces Body Weight and Food Intake in Obese Candy-Fed Rats, Whereas a Dipeptidyl Peptidase-IV Inhibitor, Vildagliptin, Does Not , 2007, Diabetes.
[17] Makoto Nishida,et al. A new simple method for the measurement of visceral fat accumulation by bioelectrical impedance. , 2005, Diabetes care.
[18] J. Holst,et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. , 2004, American journal of physiology. Endocrinology and metabolism.
[19] J. Holst,et al. The incretin approach for diabetes treatment: modulation of islet hormone release by GLP-1 agonism. , 2004, Diabetes.
[20] J. Manson,et al. Dietary fat and cholesterol and the risk of cardiovascular disease among women with type 2 diabetes. , 2004, The American journal of clinical nutrition.
[21] S. Kihara,et al. Adiponectin and Metabolic Syndrome , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[22] R. Mensink,et al. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. , 2003, The American journal of clinical nutrition.
[23] Anastasia C. Thanopoulou,et al. Dietary fat intake as risk factor for the development of diabetes: multinational, multicenter study of the Mediterranean Group for the Study of Diabetes (MGSD). , 2003, Diabetes care.
[24] R. Bergman,et al. Accurate Assessment of β-Cell Function: The Hyperbolic Correction , 2002 .
[25] M. Zdravkovic,et al. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men , 2002, Diabetologia.
[26] A. Astrup,et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. , 2001, The Journal of clinical endocrinology and metabolism.
[27] D R Jacobs,et al. Dietary fat and incidence of type 2 diabetes in older Iowa women. , 2001, Diabetes care.
[28] J. Holst,et al. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. , 1999, Diabetes care.
[29] M. Matsuda,et al. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. , 1999, Diabetes care.
[30] C. Beglinger,et al. rapid communication Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2 , 2022 .
[31] A. Astrup,et al. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. , 1998, The Journal of clinical investigation.
[32] R. Hamman,et al. High-fat, low-carbohydrate diet and the etiology of non-insulin-dependent diabetes mellitus: the San Luis Valley Diabetes Study. , 1991, American journal of epidemiology.
[33] D. Leonetti,et al. Diet of second-generation Japanese-American men with and without non-insulin-dependent diabetes. , 1990, The American journal of clinical nutrition.
[34] P. Bennett,et al. Diabetes Mellitus and Its Vascular Complications in Japanese Migrants on the Island of Hawaii , 1979, Diabetes Care.
[35] A. Dear,et al. Erratum: A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model (Diabetes and Vascular Disease Research (2011) 8:2 (117-124) DOI: 10.1177/1479164111404257) , 2012 .
[36] R. Chilton,et al. Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies. , 2011, The American journal of medicine.
[37] D. Klonoff,et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. , 2008, Current medical research and opinion.
[38] R. Bergman,et al. Accurate assessment of beta-cell function: the hyperbolic correction. , 2002, Diabetes.